# Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Canonical URL: https://biopharmsignal.com/news/MCRB/seres-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-updates
Ticker: MCRB
Company: Seres Therapeutics
Source: Seres Therapeutics
Published: 2026-05-05 11:00 EST
Original Source URL: https://ir.serestherapeutics.com
## Summary

Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected in the coming weeks Seres maintains operational focus on advancing live biotherapeutic programs in inflammatory and immune diseases Company pursuing partnerships and other

## Article Body
Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected in the coming weeks Seres maintains operational focus on advancing live biotherapeutic programs in inflammatory and immune diseases Company pursuing partnerships and other
## Recent Company News
- 2026-05-12 11:00 EST — [Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference](https://biopharmsignal.com/news/MCRB/seres-therapeutics-to-participate-in-h-c-wainwright-4th-annual-bioconnect-investor-conference) — Source: Seres Therapeutics
- 2026-05-05 11:00 EST — [Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/MCRB/seres-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-updates) — Source: Seres Therapeutics
- 2026-05-04 11:00 EST — [Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease](https://biopharmsignal.com/news/MCRB/seres-therapeutics-presents-preclinical-data-at-digestive-disease-week-ddw-2026-supporting-ser-603-a-next-generation-cultivated-live-biotherapeutic-candidate-for-inflammatory-bowel-disease) — Source: Seres Therapeutics
- 2026-04-20 11:00 EST — [Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026](https://biopharmsignal.com/news/MCRB/seres-therapeutics-showcases-ser-155-data-and-live-biotherapeutic-insights-at-escmid-global-2026) — Source: Seres Therapeutics
- 2026-04-09 11:00 EST — [Seres Therapeutics to Present at CARB-X Investor Day](https://biopharmsignal.com/news/MCRB/seres-therapeutics-to-present-at-carb-x-investor-day) — Source: Seres Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)